Bocidelpar
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
This article is a stub. |
Bocidelpar or ASP0367 or MA-0211 is an experimental drug that may improve mitochondria and endothelial function.[1] Bocidelpar is undergoing clinical trials under the name ASP0367 for Duchenne Muscular Dystrophy, ME/CFS and a number of other diseases mitochondria involving mitochondria dysfunction.[1][2]
Theory[edit | edit source]
Evidence[edit | edit source]
The first clinical trial for ME/CFS is trial NCT04855201, which has not yet published any results. The trial involves 40 adults aged between 18 and 60, and is randomized clinical trial with quadruple blinding.[2]
Clinicians[edit | edit source]
David Systrom is helping conduct the current clinical trial of bocidelpar at Brigham and Women's Hospital, Boston, United States.[3]
Risks and safety[edit | edit source]
Unknown.
Costs and availability[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
- ASP0367 (MA-0211) development pipeline
- April 2022, $8 Million Clinical Trial of a Mitochondrial Booster Underway in ME/CFS - Cort Johnson, Health Rising